---

April 13, 2025

Picture your body as a giant city, with trillions of cells working like tiny factories—heart cells pumping, immune cells battling bugs, each with its own job. Now imagine a tool that listens to one factory at a time, catching every word of its “instruction manual” to spot what’s wrong in diseases like heart failure. That’s what Scipio Bioscience, a Paris-based biotech startup, did until it closed its doors on September 18, 2024. From a clever gel kit to breakthroughs in heart research, Scipio made science easier for labs worldwide, leaving a legacy even after hitting tough times. Here’s their story—what they did, why it mattered, and why they couldn’t keep going.

Listening to Cells, One by One

Every cell has a unique role, but when diseases like cancer or heart trouble strike, scientists need to know which ones are causing chaos. Scipio Bioscience built a way to do this called single-cell RNA sequencing, or scRNA-seq. It’s like putting a microphone on each cell to hear which genes—the body’s instruction switches—are on or off. A heart cell might say, “I’m pumping!” while a sick one whispers, “I’m struggling.” By listening closely, researchers can find new ways to fix problems.

Big labs with fancy machines used to hog this tech, but Scipio wanted everyone in on the game. Their Asteria™ kit, launched in 2022, let scientists study 10,000 cells at once using just a regular lab table—no million-dollar gadgets needed. From heart cells to cancer cells, it gave a clear snapshot of what was happening inside (GenomeWeb: Asteria Launch).

A Gel That Worked Wonders

Scipio’s secret weapon was a special gel, like Jell-O with tiny rooms for each cell. This gel, called RevGel-seq™, trapped cells with a barcode—a name tag—so scientists could track whose instructions were whose. No pipes, no machines, just mix and go. Their 2024 research showed it nailed about 2,000 genes per cell, matching the big players like 10x Genomics, even for tricky heart cells (bioRxiv Pre-print).

They added Cytonaut™, a computer program that turned messy data into bright, easy maps—like a guide showing which cells were healthy or not. It was so simple, even non-techies could dig in, opening doors for labs everywhere (Scipio Bioscience Products).

Helping Hearts Beat Stronger

Scipio had a big heart—literally. They worked with Saint-Louis Hospital in Paris to study heart cells, called cardiomyocytes, which keep your ticker going. These cells are huge, making them tough to analyze, but Scipio tweaked their kit to handle them, helping scientists learn why some hearts fail and how to help. This could’ve led to new medicines to keep hearts pumping strong (Scipio Bioscience Supports).

They didn’t just focus on hearts. In 2022, Scipio gave $30,000 to researchers studying diabetes, Parkinson’s, and more, sharing their tools to fight all sorts of diseases. They popped up at science fairs, like a heart health conference in Marseille, spreading their ideas far and wide (BioPharma APAC: Scipio Grant).

Were They Good Guys?

Messing with cells raises big questions—are they doing it right? Scipio seemed to play fair. They used lab cells or hospital samples, not hurting people or animals. Places like Saint-Louis made sure patients agreed to share their cells, following strict rules. Scipio shared their work openly in papers, letting others double-check—no sneaky moves (bioRxiv Pre-print).

Could they have slipped up? Maybe. They didn’t say what their kit cost, so it’s hard to know if small labs could afford it. Big investors gave them €7.5 million, which might’ve pushed for quick bucks, but there’s no dirt on them lying or cheating. Unlike some biotech firms in trouble for shady deals, Scipio kept it clean (Markets Insider: Caribou Investigation).

Why Did They Shut Down?

Just when things looked bright, Scipio closed shop on September 18, 2024. They called it “challenges we cannot overcome,” but didn’t spill the beans (Scipio Bioscience Closure). Biotech’s a rough game—startups often run out of cash or get squashed by giants like 10x Genomics. Scipio had €7.5 million, but that might not have covered growing big or fighting off competitors. There’s no gossip about lawsuits or scandals, so it’s likely they just couldn’t keep the lights on, a sad but common end for small companies with big dreams.

Why It Still Matters

Even though Scipio’s gone, their work lives on. Their heart cell discoveries and tools are helping scientists keep digging, maybe leading to fixes for broken hearts one day. They showed that science doesn’t need big bucks or machines—just smart ideas and a gel that works magic. Their story’s a reminder: even small teams can make a dent in big problems.

What do you think cells could teach us next? Share your ideas at ashesonair.org.

Sources:

• Scipio Bioscience Website
• bioRxiv Pre-print
• GenomeWeb: Asteria Launch
• Scipio Bioscience Products
• Scipio Bioscience Supports
• BioPharma APAC: Scipio Grant
• Scipio Bioscience About
• Markets Insider: Caribou Investigation
• Scipio Bioscience Closure